The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Arthaxan     4-(6-methoxynaphthalen-2- yl)butan-2-one

Synonyms: Consolan, Dolsinal, Flambate, Arthraxan, Listran, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Dolsinal


Psychiatry related information on Dolsinal

  • The nabumetone 1500-mg group showed significantly greater responses than the placebo group in vitality (P < 0.05), mental health (P < 0.01), and MCS score (P < 0.001) [6].

High impact information on Dolsinal


Chemical compound and disease context of Dolsinal

  • This six-month, double-blind, controlled, randomized, parallel study at 13 medical centers compared the safety and efficacy of nabumetone (1,000 mg taken at bedtime) with that of naproxen (250 mg twice daily) in the treatment of osteoarthritis in symptomatic adult outpatients [12].
  • BACKGROUND: Prophylactic misoprostol or non-steroidal anti-inflammatory drugs (NSAIDs) with low gastric toxicity (nabumetone) has been shown to reduce mucosal injury [13].
  • Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers [14].
  • The efficacy, tolerability, and safety of 1200 mg/d of oxaprozin and 1500 mg/d of nabumetone in the treatment of patients with osteoarthritis of the knee [15].
  • The results of this study demonstrate that treatment with nabumetone or sulindac caused no deterioration in renal function in older female patients with osteoarthritis and normal renal function [16].

Biological context of Dolsinal


Anatomical context of Dolsinal


Associations of Dolsinal with other chemical compounds


Gene context of Dolsinal


Analytical, diagnostic and therapeutic context of Dolsinal


  1. Nabumetone therapy of osteoarthritis. A six-week, placebo-controlled study. Blechman, W.J. Am. J. Med. (1987) [Pubmed]
  2. Nabumetone in the treatment of skin and soft tissue injury. Jenner, P.N. Am. J. Med. (1987) [Pubmed]
  3. Efficacy and safety of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in the elderly. Morgan, G.J., Poland, M., DeLapp, R.E. Am. J. Med. (1993) [Pubmed]
  4. Long-term treatment of rheumatoid arthritis comparing nabumetone with aspirin. Bernhard, G.C., Appelrouth, D.J., Bankhurst, A.D., Biundo, J., Bockow, B.I., Brobyn, R.D., Brodsky, A.L., Burch, F.X., Chang, R.W., Cohen, M.H. Am. J. Med. (1987) [Pubmed]
  5. Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. Eversmeyer, W., Poland, M., DeLapp, R.E., Jensen, C.P. Am. J. Med. (1993) [Pubmed]
  6. Health-related quality-of-life effects of oxaprozin and nabumetone in patients with osteoarthritis of the knee. Zhao, S.Z., Dedhiya, S.D., Bocanegra, T.S., Fort, J.G., Kuss, M.E., Rush, S.M. Clinical therapeutics. (1999) [Pubmed]
  7. A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Elliott, S.N., McKnight, W., Cirino, G., Wallace, J.L. Gastroenterology (1995) [Pubmed]
  8. Rationalizing cyclooxygenase (COX) inhibition for maximal efficacy and minimal adverse events. Freston, J.W. Am. J. Med. (1999) [Pubmed]
  9. Gastrointestinal safety profile of nabumetone: a meta-analysis. Huang, J.Q., Sridhar, S., Hunt, R.H. Am. J. Med. (1999) [Pubmed]
  10. Mitochondrial damage: a possible mechanism of the "topical" phase of NSAID induced injury to the rat intestine. Somasundaram, S., Rafi, S., Hayllar, J., Sigthorsson, G., Jacob, M., Price, A.B., Macpherson, A., Mahmod, T., Scott, D., Wrigglesworth, J.M., Bjarnason, I. Gut (1997) [Pubmed]
  11. PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs. DeWitt, D.L., Meade, E.A., Smith, W.L. Am. J. Med. (1993) [Pubmed]
  12. Six-month multi-center study comparing nabumetone with naproxen in the treatment of osteoarthritis. Pisko, E.J., Bockow, B.I., Box, P., Brodsky, A.L., Burch, F.X., Collins, R.L., Fleischmann, R.M., Keller, M.I., Lipani, J.A., Poiley, J.E. Am. J. Med. (1987) [Pubmed]
  13. Randomized trial of low-dose misoprostol and naproxen vs. nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non-steroidal anti-inflammatory drugs. Chan, F.K., Sung, J.J., Ching, J.Y., Wu, J.C., Lee, Y.T., Leung, W.K., Hui, Y., Chan, L.Y., Lai, A.C., Chung, S.C. Aliment. Pharmacol. Ther. (2001) [Pubmed]
  14. Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. Agrawal, N.M., Caldwell, J., Kivitz, A.J., Weaver, A.L., Bocanegra, T.S., Ball, J., Dhadda, S., Hurley, S., Hancock, L. Clinical therapeutics. (1999) [Pubmed]
  15. The efficacy, tolerability, and safety of 1200 mg/d of oxaprozin and 1500 mg/d of nabumetone in the treatment of patients with osteoarthritis of the knee. Makarowski, W., Weaver, A., Rubin, B., Caldwell, J., McMahon, F.G., Noveck, R.J., Lee, D., Offenberg, H., Sack, M., Sikes, D., Trapp, R., Rush, S., Kuss, M., Ganju, J., Bocanegra, T.S., Ratliff, J.M. Clinical therapeutics. (1996) [Pubmed]
  16. Renal hemodynamic effects of nabumetone, sulindac, and placebo in patients with osteoarthritis. Cangiano, J.L., Figueroa, J., Palmer, R. Clinical therapeutics. (1999) [Pubmed]
  17. Nabumetone pharmacokinetics in patients with varying degrees of renal impairment. Boelaert, J.R., Jonnaert, H.A., Daneels, R.F., Schurgers, M.L., Thawley, A.R., Undre, N.A., Cooper, D.L. Am. J. Med. (1987) [Pubmed]
  18. Nonsteroidal antiinflammatory drug use in patients receiving warfarin: emphasis on nabumetone. Hilleman, D.E., Mohiuddin, S.M., Lucas, B.D. Am. J. Med. (1993) [Pubmed]
  19. Preclinical overview of nabumetone. Pharmacology, bioavailability, metabolism, and toxicology. Mangan, F.R., Flack, J.D., Jackson, D. Am. J. Med. (1987) [Pubmed]
  20. Bioequivalence study of nabumetone: tablet versus suspension. Daigneault, E.A., Ferslew, K.E., Stanton, P. Am. J. Med. (1987) [Pubmed]
  21. Nabumetone kinetics in the young and elderly. McMahon, F.G., Vargas, R., Ryan, J.R., Fitts, D.A. Am. J. Med. (1987) [Pubmed]
  22. Radiochromium (chromium-51) evaluation of gastrointestinal blood loss associated with placebo, aspirin, and nabumetone. Lussier, A., LeBel, E. Am. J. Med. (1987) [Pubmed]
  23. Nonsteroidal anti-inflammatory drug therapy and gastric side effects. Does nabumetone provide a solution? Dandona, P., Jeremy, J.Y. Drugs (1990) [Pubmed]
  24. Penetration of the active metabolite of nabumetone into synovial fluid and adherent tissue of patients undergoing knee joint surgery. Miehlke, R.K., Schneider, S., Sörgel, F., Muth, P., Henschke, F., Giersch, K.H., Münzel, P. Drugs (1990) [Pubmed]
  25. Evaluation of hydroxyimine as cytochrome P450-selective prodrug structure. Kumpulainen, H., Mähönen, N., Laitinen, M.L., Jaurakkajärvi, M., Raunio, H., Juvonen, R.O., Vepsäläinen, J., Järvinen, T., Rautio, J. J. Med. Chem. (2006) [Pubmed]
  26. Endoscopy-controlled study of the safety of nabumetone compared with naproxen in arthritis therapy. Roth, S.H. Am. J. Med. (1987) [Pubmed]
  27. NSAID gastropathy. The central issue. Roth, S.H. Drugs (1990) [Pubmed]
  28. Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Smith, W.L., Meade, E.A., DeWitt, D.L. Ann. N. Y. Acad. Sci. (1994) [Pubmed]
  29. Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. Hedner, T., Samulesson, O., Währborg, P., Wadenvik, H., Ung, K.A., Ekbom, A. Drugs (2004) [Pubmed]
  30. Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Reichman, J., Cohen, S., Goldfarb, M., Shina, A., Rosen, S., Brezis, M., Karmeli, F., Heyman, S.N. Exp. Nephrol. (2001) [Pubmed]
  31. Safety evaluation of nabumetone in United States clinical trials. Jackson, R.E., Mitchell, F.N., Brindley, D.A. Am. J. Med. (1987) [Pubmed]
  32. Endoscopic studies of nabumetone in patients with rheumatoid arthritis. A comparative endoscopic and histologic evaluation. Greb, W.H., von Schrader, H.W., Cerlek, S., Dominis, M., Hauptmann, E., Zenić, N. Am. J. Med. (1987) [Pubmed]
  33. Population pharmacokinetics of the active metabolite of nabumetone in renal dysfunction. Brier, M.E., Sloan, R.S., Aronoff, G.R. Clin. Pharmacol. Ther. (1995) [Pubmed]
WikiGenes - Universities